Benign Prostatic Hyperplasia/Urinary Retention
Researchers conducted a retrospective matched cohort study to compare the risk of death among BPH patients treated with 5ARIs, as monotherapy or in combination with alpha-blockers, and those treated with alpha-blockers alone.
"We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC," said Michael Cookson, MD, member of the 2018 amendment panel.
The new guideline includes 22 recommendations focused on utilizing common surgical techniques and minimally invasive surgical therapies.
Nearly 7,000 Italian men participating in the Moli-sani epidemiological study aged ≥50 years were monitored for an average of 4.25 years.
The USPSTF performed a systematic review of the existing evidence and concluded that the potential benefits and harms of prostate-specific antigen (PSA)-based screening are "closely balanced" in men aged 55-69 years.
No increase in risk of suicide was found but an increased risk of self-harm and depression was noted during initial 18 months after initiation of 5-reductase.
The data showed adult males who used 5 alpha-reductase inhibitors did not exhibit a significantly increased risk of suicide, however the risk of self-harm did increase.
Nymox announced positive data from the Phase 3 study of fexapotide for the treatment of benign prostatic hyperplasia (BPH) and localized prostate cancer.
Age and obesity affect gene regulation in men with symptomatic benign prostatic hyperplasia, according to a study published in The Journal of Urology.
A review in the journal Endocrine Reviews and Metabolic Disorders reports that greater education and awareness of the potential risks associated with two treatments for benign prostate hyperplasia (BPH) is needed among both patients and clinicians, along with additional research exploring these reported adverse effects.
Men treated for benign prostatic hyperplasia (BPH) with the type II 5 alpha-reductase inhibitor finasteride could be significantly more likely to experience erectile dysfunction (ED) compared to those taking the alpha-1A blocker tamsulosin.
The Food and Drug Administration (FDA) is warning healthcare professionals and consumers that counterfeit versions of Cialis (tadalafil; Eli Lilly) 20mg tablets were discovered in the mail in transit to a U.S. consumer.
Metabolic abnormalities such as metabolic syndrome and insulin resistance are associated with lower urinary tract symptoms (LUTS), according to two studies.
The risk of developing postoperative urinary retention (POUR) after posterior lumbar spine surgery is approximately 5%, with certain patient factors associated with higher risk.
Researchers have evaluated urologist adherence to the American Urological Association (AUA) guidelines for the management of benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS).
Because α1-AR appear to have a role in lower urinary tract function, the use of α1-AR antagonists like tamsulosin may be effective for female patients with dysfunctional voiding.
Can supplementing with pumpkin seed improve lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH)?